Latest Ascletis Pharma News
Mar 30, 2021
publication date: Mar 30, 2021 Hangzhou 's Ascletis Pharma announced that it will expand its focus into oncology. The company was founded to bring effective hepatitis C treatments to China at an affordable price. It has accomplished that, and it now plans to combine its two in-licensed FASN inhibitors with two self-discovered anti-cancer drugs, an EGFR anti-angiogenesis candidate (bevacizumab) and a small molecule PD-1 inhibitor. Initially, it will test a combination of ASC40 and bevacizumab in patients with astrocytoma, a cancer of the brain or spinal cord.